XFOR Non Current Liabilities Total vs Non Current Assets Total Analysis
XFOR Stock | USD 0.94 0.04 4.44% |
X4 Pharmaceuticals financial indicator trend analysis is more than just analyzing X4 Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether X4 Pharmaceuticals is a good investment. Please check the relationship between X4 Pharmaceuticals Non Current Liabilities Total and its Non Current Assets Total accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.
Non Current Liabilities Total vs Non Current Assets Total
Non Current Liabilities Total vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of X4 Pharmaceuticals Non Current Liabilities Total account and Non Current Assets Total. At this time, the significance of the direction appears to have weak relationship.
The correlation between X4 Pharmaceuticals' Non Current Liabilities Total and Non Current Assets Total is 0.31. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of X4 Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of X4 Pharmaceuticals' Non Current Liabilities Total and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of X4 Pharmaceuticals are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Non Current Liabilities Total i.e., X4 Pharmaceuticals' Non Current Liabilities Total and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.31 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Non Current Liabilities Total
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from X4 Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.As of 05/30/2024, Enterprise Value is likely to grow to about 130.3 M, while Selling General Administrative is likely to drop slightly above 19.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Tax Provision | 17K | 28K | 59K | 50.4K | Reconciled Depreciation | 499K | 513K | 481K | 361.0K |
X4 Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
X4 Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
X4 Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 160.7M | 122.9M | 117.2M | 155.6M | 147.3M | 102.4M | |
Short Long Term Debt Total | 22.9M | 38.4M | 39.8M | 38.4M | 58.3M | 29.4M | |
Other Current Liab | 6.5M | 8.0M | 7.9M | 12.0M | 12.8M | 7.4M | |
Total Current Liabilities | 9.4M | 11.9M | 14.0M | 22.3M | 22.9M | 13.7M | |
Total Stockholder Equity | 129.2M | 72.8M | 64.4M | 74.1M | 51.1M | 46.6M | |
Property Plant And Equipment Net | 2.4M | 9.2M | 10.2M | 8.3M | 6.4M | 4.7M | |
Net Debt | (103.3M) | (40.3M) | (42.0M) | (83.3M) | (41.2M) | (43.2M) | |
Retained Earnings | (132.0M) | (194.2M) | (282.9M) | (376.7M) | (477.9M) | (454.0M) | |
Accounts Payable | 2.1M | 3.1M | 4.3M | 7.8M | 8.9M | 9.4M | |
Cash | 126.2M | 78.7M | 81.8M | 121.7M | 99.5M | 76.4M | |
Non Current Assets Total | 31.4M | 39.6M | 29.3M | 26.9M | 25.2M | 19.2M | |
Non Currrent Assets Other | 1.9M | 3.3M | 1.7M | 1.2M | 654K | 621.3K | |
Cash And Short Term Investments | 126.2M | 78.7M | 81.8M | 121.7M | 114.5M | 78.2M | |
Net Receivables | 2.0M | 917K | 747K | 1.2M | 562K | 533.9K | |
Common Stock Shares Outstanding | 11.5M | 20.1M | 25.7M | 63.5M | 177.8M | 186.7M | |
Liabilities And Stockholders Equity | 160.7M | 122.9M | 117.2M | 155.6M | 147.3M | 102.4M | |
Non Current Liabilities Total | 22.0M | 38.1M | 38.7M | 59.2M | 73.3M | 42.1M | |
Other Current Assets | 1.1M | 3.7M | 5.3M | 5.8M | 7.0M | 7.4M | |
Other Stockholder Equity | 100.7M | 267.1M | 347.4M | 450.8M | 529.0M | 555.4M | |
Total Liab | 31.5M | 50.1M | 52.8M | 81.5M | 96.2M | 55.9M | |
Property Plant And Equipment Gross | 2.4M | 9.2M | 10.2M | 8.3M | 8.0M | 4.9M | |
Total Current Assets | 129.3M | 83.3M | 87.9M | 128.7M | 122.1M | 83.3M | |
Short Term Debt | 898K | 786K | 1.9M | 2.5M | 1.1M | 1.7M | |
Other Liab | 16K | 462K | 826K | 23.3M | 26.8M | 28.1M | |
Net Tangible Assets | 102.1M | 45.7M | 47.1M | 56.7M | 65.2M | 68.5M | |
Long Term Debt | 20.1M | 33.2M | 33.1M | 32.3M | 54.6M | 27.7M | |
Short Long Term Debt | 2.3M | 1.7M | 795K | 1.3M | 1.2M | 1.8M | |
Non Current Liabilities Other | 16K | 462K | 826K | 3.6M | 432K | 748K | |
Property Plant Equipment | 2.4M | 9.2M | 10.2M | 1.1M | 1.3M | 1.2M | |
Capital Surpluse | 156.6M | 261.4M | 267.1M | 450.8M | 518.4M | 283.1M | |
Net Invested Capital | 149.3M | 106.0M | 98.3M | 107.7M | 105.7M | 104.9M | |
Net Working Capital | 119.8M | 71.4M | 73.9M | 106.4M | 99.2M | 89.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for XFOR Stock analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Return On Assets (0.61) | Return On Equity (4.89) |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.